Information for Clinical Trial Participants
Find a Clinical Trial at NIH
You can use the NIH Clinical Center's Search the Studies tool to search for clinical trials occurring at NIH
Find Information on All Clinical Trials
You can use the National Library of Medicine's Clinical Trial Search for information on all active clinical trials.
Questions & Concerns about an Ongoing Study at NIH
You can contact OHSRP by phone (301) 402-3713 or by email at email@example.com. Our main office is located at 6700B Rockledge Drive, Suite 4300, Bethesda, MD 20897.
Please note, if you send information to the email above, please do not include sensitive information or personal health information.
About the Office of Human Subjects Research Protection (OHSRP)
The Office of Human Subjects Research Protections (OHSRP) carries out the day-to-day operations and regulatory oversight of human research activities within the Human Research Protections Program (HRPP). The OHSRP promotes the protection of rights, safety and welfare of human subjects, and the NIH’s research mandate. You can find more information on our About page.
Right To Try
Federal and state Right to Try laws generally permit the use of unapproved, experimental drugs and biological products by individuals diagnosed with a life-threatening condition who (1) have exhausted approved treatment options, and (2) are unable to participate in clinical trials involving the product.
However, NIH is a federal research agency. Therefore, it cannot provide an unapproved drug or biological product to an individual unless the subject is enrolled in an NIH protocol. Further, Right to Try laws do not establish a “right” to participate in a clinical trial or protocol, i.e., the laws do not entitle patients to participate in an NIH-sponsored clinical trial.
If you are unable to enroll in an NIH protocol involving an unapproved drug or biological product, the Right to Try Act may provide another option. Interested individuals should speak to their home-based treating physician about the possibility of receiving an unapproved drug or biological product from a source other than the NIH through the Right to Try pathway. The federal Right to Try Act became law on May 30, 2018. More information is available at https://www.congress.gov/bill/115th-congress/senate-bill/204/text.